NVCHI
UTHR icon

New Vernon Capital Holdings II’s United Therapeutics UTHR Stock Holding History

New Vernon Capital Holdings II’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,697
Closed -$952K – 87
2024
Q4 		$952K Hold
2,697
– – 0.65% 15
2024
Q3 		$966K Hold
2,697
– – 0.52% 21
2024
Q2 		$859K Hold
2,697
– – 0.46% 19
2024
Q1 		$620K Buy
2,697
+92
+4% +$20.8K 0.32% 32
2023
Q4 		$573K Buy
+2,605
New +$600K 0.31% 40
2019
Q1 		– Sell
-3,366
Closed -$367K – 37
2018
Q4 		$367K Buy
3,366
+807
+32% +$93.6K 0.57% 23
2018
Q3 		$327K Hold
2,559
– – 0.34% 27
2018
Q2 		$290K Buy
+2,559
New +$281K 0.32% 27

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

New Vernon Capital Holdings II's UTHR Position: Q1 2025 in Review

New Vernon Capital Holdings II sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 2,697 shares — an estimated $952K sold.

New Vernon Capital Holdings II first reported a position in UTHR in Q2 2018 and held it in 8 quarters. The position peaked at $966K in Q3 2024. 673 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • New Vernon Capital Holdings II reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • New Vernon Capital Holdings II sold 2,697 United Therapeutics shares in Q1 2025, an estimated $952K.
  • New Vernon Capital Holdings II first reported a position in United Therapeutics in Q2 2018 and held it in 8 quarters.
  • New Vernon Capital Holdings II's United Therapeutics position peaked at $966K in Q3 2024.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on New Vernon Capital Holdings II's 13F filing for Q1 2025, filed 15 May 2025.